epidemiological evidence for mdma/ecstasy dependence
DESCRIPTION
Epidemiological Evidence for MDMA/Ecstasy Dependence. Linda B. Cottler, Ph.D Department of Psychiatry Director, Epidemiology & Prevention Research Group Washington University School of Medicine St. Louis 23 January, 2007. Acknowledgements. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/1.jpg)
Epidemiological Evidence for MDMA/Ecstasy Dependence
Linda B. Cottler, Ph.DDepartment of Psychiatry
Director, Epidemiology & Prevention Research Group
Washington University School of Medicine
St. Louis
23 January, 2007
![Page 2: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/2.jpg)
Acknowledgements
NIDA T32, R01s, R21, Single Source Contract (Taiwan)
NIAAA NINR Fogarty International Center Training Grant
![Page 3: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/3.jpg)
Disclosures
No pharmaceutical or other COI
![Page 4: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/4.jpg)
Ecstasy
3,4-methylene dioxy-N-methyl amphetamine
MDMA
![Page 5: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/5.jpg)
![Page 6: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/6.jpg)
![Page 7: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/7.jpg)
History
Developed in Germany in early 1900s to synthesize other pharmaceuticals
Used in 1970s by psychiatrists as a psychoactive tool (called “penicillin for the soul”)
1980s used on the street; 1990s at raves 2000 approved by FDA for use in RCT for PTSD Both a stimulant and psychedelic Taken orally, effect lasts 3 to 6 hours Average dose is 1 to 2 tablets (each 60 to 120 mg)
![Page 8: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/8.jpg)
![Page 9: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/9.jpg)
Scheduling
Schedule I. (A) The drug or other substance has a high potential for abuse. (B) The drug or other substance has no currently accepted medical use in treatment in the United States. (C) There is a lack of accepted safety for use of the drug or other substance under medical supervision. The substance has a high potential for abuse.
Examples: MDMA, Heroin, Marijuana, LSD, Mescaline, Peyote
![Page 10: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/10.jpg)
Scheduling
Schedule II. (A) The drug or other substance has a high potential for abuse. (B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. (C) Abuse of the drug or other substances may lead to severe psychological or physical dependence.
Examples: Amphetamine, Cocaine, Ritalin, Methadone, Oxycodone
![Page 11: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/11.jpg)
Scheduling
Schedule III. (A) The drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II.(B) The drug or other substance has a currently accepted medical use in treatment in the United States. (C) Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.
Examples: Anabolic steroids, Codeine, Ketamine
![Page 12: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/12.jpg)
Scheduling
Schedule IV. (A) The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule III.(B) The drug or other substance has a currently accepted medical use in treatment in the United States. (C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III.
Examples: Xanax, Librium, Valium, Rohypnol, Provigil, Ambien, Ativan
![Page 13: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/13.jpg)
Scheduling
Schedule V. (A) The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV. (B) The drug or other substance has a currently accepted medical use in treatment in the United States. (C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV.
Examples: Robitussin C, Lomotil
![Page 14: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/14.jpg)
For Today
Whether there is epidemiological evidence for MDMA/Ecstasy dependence
Whether the evidence might suggest a separate category in the DSM
![Page 15: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/15.jpg)
In the Future
Realization that this is only part of the evidence
Efforts are still under way and many investigators have puzzle pieces
![Page 16: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/16.jpg)
Review of Criteria--DSM-IV Abuse--
Recurrent use resulting in failure to meet role obligations at work, home or school
Recurrent use in situations when it is likely to be physically hazardous
Legal problems resulting from recurrent use Continued use despite knowledge that it is
causing social/interpersonal problems At least one of the above is required for the disorder Dependence must not have been met
![Page 17: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/17.jpg)
Review of Criteria--DSM-IV Dependence--
Tolerance Withdrawal Taking substance for longer time or larger amounts than
intended Persistent desire or unsuccessful efforts to quit or cut down Great deal of time spent in activities to obtain or recover
from the effects of the drug Important social or occupational activities given up in order
to use Continued use despite knowledge of physical/
psychological problems caused by substance
Maladaptive pattern of use, evidenced by at least 3 of the above in any one 12 month period
![Page 18: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/18.jpg)
The DSM Category
There is no separate category for Ecstasy and its isomers.
Currently, Ecstasy is lumped with hallucinogens.
![Page 19: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/19.jpg)
Use of Ecstasy among 8th,10th and 12th graders--Monitoring the Future Data
0
2
4
6
8
10
12
95 96 97 98 99 '00 '02 '05
8th10th12th
//
![Page 20: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/20.jpg)
Perceived Harmfulness of Obtaining EcstasyReported by 12th Graders (MTF Data)
0
10
20
30
40
50
60
70
80
'00 '01 '02 '03 '04 '05
% whothinkMDMA isharmful
![Page 21: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/21.jpg)
“Research in animals indicates that MDMA is neurotoxic; whether or not this is also true in humans is currently an area of intense investigation. MDMA can also be dangerous to health and, on rare occasions, lethal.”
![Page 22: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/22.jpg)
What the Public has been told aboutthe Risks of Ecstasy
It damages brain cells, even in occasional users.
Causes increased heart rate, blood pressure, body temperature.
Not benign. Alan Leshner, former Director, NIDA (2002);
current CEO of AAAS (publisher of Science)
![Page 23: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/23.jpg)
What the Public has been told aboutthe Risks of Ecstasy
“…it is a drug that is far from benign. For example, MDMA can cause a dangerous increase in body temperature that can lead to kidney failure. MDMA can also increase heart rate, blood pressure, and heart wall stress. Animal studies show that MDMA can damage specific neurons in the brain. In humans, the research is not conclusive at this time; however, a number of studies show that long-term, heavy MDMA users suffer cognitive deficits, including problems with memory.”
Nora Volkow, Director, NIDA (2002)
![Page 24: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/24.jpg)
March 2006, printed
![Page 25: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/25.jpg)
What is known about Ecstasy Topp and colleagues (1997) did the first study of DSM-IV
abuse/dependence on Ecstasy (Sydney, n=185) and found that: problems from Ecstasy use exist reliability and validity of these criteria were needed 64% met criteria for dependence, 21% met criteria for abuse the most prevalent criteria reported were withdrawal,
tolerance, and unsuccessful efforts to stop use Cottler and colleagues (2001), using the SAM, found that:
reports of criteria were reliable 43% met criteria for dependence 34% met criteria for abuse the most prevalent criteria reported were withdrawal (59%),
physically hazardous use (43%), and continuing to use despite knowledge of harm (63%)
![Page 26: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/26.jpg)
Opportunity
NIDA-funded study focuses on: Reliability (test-retest) and validity (clinical
evaluation) of club drug use disorders Revision to the Composite International Diagnostic
Interview-- Substance Abuse Module (CIDI-SAM) New Risk Behavior Assessment specific to club drugs 2 sites: St. Louis, Miami (3rd site added with an
international supplement: Sydney; 4th site added with a contract: Taipei and included MRI)
+ Qualitative methods + STD testing and drug testing (via hair)
![Page 27: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/27.jpg)
Miami collaborators
Jim Inciardi, PhD Hilary Surratt, PhD Steve Kurtz, PhD
![Page 28: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/28.jpg)
Jan Copeland, PhD, Maree Teesson, PhD
National Drug and Alcohol Research Center, NSW
Sydney collaborators
![Page 29: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/29.jpg)
Design:
(SCAN) Clinical Interview (N=295)
(N=305)(N=305)
Random assignment
(1:2)
Time I(N = 637)
Subjects receive: RBA, SAM, CES-D
Subjects receive: RBA SAM
Subjects receive: RBA SAM
Time II
Eligibility: 18 to 35 years of age; recruited via flyers, newspaper, respondent driven methods; used XTC at least 5 x LT; once in past 12 months
![Page 30: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/30.jpg)
Characteristics of Tri-City Study of Ecstasy Dependence
Miami(n=186)
St. Louis(n=297)
Sydney(n=154)
p value
Female
Mean Age
Caucasian
39%
23.6
31%
44%
23.3
73%
39%
23.0
79%
N/S
N/S
.0001
Ever Married 9% 8% 1% .01
Employed (any in past 12m) 94% 91% 92% N/S
Cannabis (LT) 98% 99% 94% N/S
Stimulants (LT)
GHB (LT)
Rohypnol (LT)
Ketamine (LT)
Hallucinogens (LT)
46%
26%
29%
37%
76%
58%
14%
5%
32%
65%
89%
13%
4%
34%
44%
.0001
.001
.0001
N/S
.0001
![Page 31: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/31.jpg)
Sir Bradford Hill’s Criteria for Causal Inference Should be Used to Decide on Acceptance of Revisions to Criteria
Consistency of findings, replicability Strength of the association Dose-response or biological gradient Temporal sequence Biological plausibility Specificity of findings
![Page 32: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/32.jpg)
Sir Bradford Hill’s Criteria for Causal Inference Should be Used to Decide on Acceptance of Revisions to Criteria
Consistency of findings, replicability Strength of the association Dose-response or biological gradient Temporal sequence Biological plausibility Specificity of findings
![Page 33: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/33.jpg)
“Adopted” DSM-IV Criteria for Ecstasy Abuse
Miami(n=186)
St. Louis(n=297)
Sydney(n=154)
p value
Use results in failure to fulfill major role obligations
24%
21% 38% .0003
Use in hazardous situations
51% 50% 54% N/S
Substance-related legal problems
7% 3% 4% N/S
Use despite knowledge it caused social problems
29% 25% 32% N/S
![Page 34: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/34.jpg)
“Adopted” DSM-IV Criteria for Ecstasy Dependence
Miami(n=186)
St. Louis(n=297)
Sydney(n=154)
p value
Tolerance
Withdrawal
Takes substance in larger amounts or over longer period
56%
68%
48%
43%
65%
37%
55%
77%
47%
.006
.03
.04
Inability to cut down or control use
18% 14% 21% N/S
Great deal of time is spent using or recovering from use
62% 48% 62% .002
Important activities are given up for substance
25% 21% 35% .005
Substance is used despite knowledge it causes physical or psychological harm
90% 85% 90% N/S
![Page 35: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/35.jpg)
“Adopted” DSM-IV Ecstasy Use Disorder
Miami(n=183)
St. Louis(n=279)
Sydney(n=143)
Neither
Abuse Only
Dependence
(+/- Abuse)
21%
16%
63%
32%
16%
52%
24%
10%
66%
X2=11.26 (4 df) p=.02
![Page 36: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/36.jpg)
Tolerance and Ecstasy
31% found in Verduin et al study. 50% found in Tri-city study, Bradford et al study.
(9% tolerance only; 49% along with withdrawal) Subtype with both tolerance and withdrawal most
prevalent (41%); w/d only 28%; neither 22% and tolerance only 9%.
Those with both were more likely to meet criteria for dependence (+/- abuse); least likely to meet abuse only, use more pills lifetime and have youngest age of onset of Ecstasy use
![Page 37: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/37.jpg)
Test/Re-test
Abuse criteria: kappas between 0.58 and 0.77
Dependence criteria: kappas between 0.51 and 0.75.
![Page 38: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/38.jpg)
St. Louis Design:
Sub-study Group B (St. Louis):Do not meet withdrawal criteria from SAM (time 1) interview, N=75
(SCAN) Clinical Interview (N=150)
(N=150)(N=150)
Random assignment
(1:2)
Time I(N = 300)
Sub-study A (St. Louis):Meet withdrawal criteria from SAM (time 1) interview, N=75
Random assignment
(1:3)
Random assignment
(1:3)
Ethnographic Sub-study (N=50)
(N=25)(N=25)
Subjects receive: RBA SAM
Subjects receive: RBA SAM
Subjects receive: RBA SAM
Time II
Eligibility: 18 to 35 years of age; recruited via flyers, newspaper, chain referral methods
![Page 39: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/39.jpg)
Sir Bradford Hill’s Criteria for Causal Inference Should be Used to Decide on Acceptance of Revisions to Criteria
Consistency of findings, replicability Strength of the association Dose-response or biological gradient Temporal sequence Biological plausibility Specificity of findings
![Page 40: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/40.jpg)
How to Obtain Dosage
RBA questions: “If you were to add up all of the ecstasy pills you
have used since you first started using ecstasy, about how many pills would that be?”
“How many days have you used ecstasy in the last 30 days?”
“During these days [when you used], how many times a day did you usually use ecstasy or MDMA?”
![Page 41: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/41.jpg)
Patterns of Lifetime Ecstasy Use
Lifetime # of pills*
Miami(n=186)
St. Louis(n=297)
Sydney(n=154)
Mean(SD)
1-99 (n=387; 4-99)
100-499 (n=178; 100-482)
500+ (n=72; 500-5200)
57%
32%
11%
68%
23%
9%
51%
32%
17%
30.5
(22.1)
214.5
(103.0)
1341.1
(1118.4)
*X2=15.9 (4 df) p=.03
Mean # pills (SD)
255.34(608.49)
181.14
(525.62)
271.94
(495.01)
224.8(543.9)
![Page 42: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/42.jpg)
“Adopted” DSM-IV Abuse Criteria by Pill Use
0
20
40
60
80
100
Neglected obligations Hazardous Use Legal problems Use despite social problems
1-99 pills (n=387) 100-499 pills (n=178) 500+ pills (n=69)
p<.0001
p<.0001
p<.0001
p<.0001
![Page 43: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/43.jpg)
“Adopted” DSM-IV Dependence Criteria by Pill Use
0
20
40
60
80
100
Tolerance Withdrawal Takes substance inlarger amounts or
over longer period
Can't cut down or control use
Much time spentusing/recovering
from use
Important activities given up for substance
Substance useddespite knowing itcaused physical or psychological harm
1-99 pills (n=387) 100-499 pills (n=178) 500+ pills (n=69)
p<.0001
p<.0001 p<.0001
p<.0001
p<.0001
p=.0014p<.0001
![Page 44: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/44.jpg)
Sir Bradford Hill’s Criteria for Causal Inference Should be Used to Decide on Acceptance of Revisions to Criteria
Consistency of findings, replicability Strength of the association Dose-response or biological gradient Temporal sequence Biological plausibility Specificity of findings
![Page 45: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/45.jpg)
Effects
Positive: mental stimulation, emotional warmth, empathy towards others, general sense of well-being, decreased anxiety
Negative/Undesirable: anxiety, agitation, recklessness, nausea, chills, sweating, muscle cramping, blurred vision, jaw clenching, dehydration, high blood pressure, heart failure, kidney failure, arrhythmia, loss of consciousness, seizures, hyperthermia
![Page 46: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/46.jpg)
![Page 47: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/47.jpg)
![Page 48: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/48.jpg)
![Page 49: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/49.jpg)
![Page 50: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/50.jpg)
![Page 51: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/51.jpg)
Focus Group Responses
• The low is as low as the high. 32 y/o Female
• I have made a conscious effort not to drive when I am on X, but sometimes parties get busted and then people need to drive. 30 y/o male
• Self-experience is the best way for knowledge. 25 y/o male
![Page 52: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/52.jpg)
• I know that E is used intravenously. They crush up a pill into powder form, put it into a spoon, mix it with water, you know, put it up. I don’t think they cook it like heroin, but I’m not sure. There are fillers that are dangerous, cause you don’t know what else is in it, but that’s what your liver’s for. 33 y/o male
• I can use drugs professionally. I’m a professional drug user in the fact that I’ve used drugs since I was 16, and I’ve used quite a few. Even when I was 17, and 18, I felt that after I had initially gotten the gist of it that I knew what my boundaries were. I knew when and where to go to do it. I knew the effects that I was going to have so I would plan for what I was going to do. 24 y/o female
• Just use 5HT on Monday, and you’ll restore your serotonin. 24 y/o female
![Page 53: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/53.jpg)
• I think that from everyone that I’ve known that has done ecstasy and myself, I’ve never known it to be an addictive drug. 24 y/o female
• I was pretty sure I was getting MDMA because I always got it from the same person and he was like a chemical engineering major. He looked like he knew what he was doing. But he never put it in pills for us and put logos on it; he only did that when he packaged it to sell it to other people. We always got it as powder. 20 y/o male
• I felt it on Suicide Tuesday– the day after the day I was recovering– was awful. (multiple users)
![Page 54: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/54.jpg)
Sir Bradford Hill’s Criteria for Causal Inference Should be Used to Decide on Acceptance of Revisions to Criteria
Consistency of findings, replicability Strength of the association Dose-response or biological gradient Temporal sequence Biological plausibility Specificity of findings
![Page 55: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/55.jpg)
Table 3. Mean number of Physical Conditions in Young, Low-Income Women (n = 696)Wu et al, CPDD Poster Presentation. 2006
Ecstasy(n = 106)
Other illicit drugs(n = 64)
Marijuana only
(n = 173)None
(n = 343)
Diabetes 4.04 0.00 0.61 2.45
Hypertension 1.00 3.45 3.68 3.67
Heart disease 2.02 0.00 0.00 0.91
Kidney disease 4.95 0.00 1.85 0.92
Gall bladder 7.07 7.02 1.23 3.38
Breast disease 5.26 1.89 3.77 3.24
Total Physical condition
0 67.96 81.03 79.88 79.76
1 22.33 13.79 17.07 18.82
2+ 9.71 5.17 3.05 2.42
![Page 56: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/56.jpg)
Specificity of Ecstasy Dependence
Miami(n=183)
St. Louis(n=279)
Sydney(n=143)
p value
Ecstasy Dependence
Alcohol Dependence
Cannabis Dependence
63%
62%
59%
52%
60%
56%
66%
61%
50%
.02
N/S
N/S
Stimulant Dependence 28% 35% 47% .008
Cocaine Dependence 57% 58% 15% .0001
Hallucinogen Dependence 35% 30% 18% .004
GHB Dependence
Ketamine Dependence
Rohypnol Dependence
ALL AMONG USERS OF THAT SPECIFIC SUBSTANCE ONLY
14%
0%
9%
13%
0%
7%
10%
0%
0%
.04
N/S
N/S
![Page 57: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/57.jpg)
Latent Class Analysis of Ecstasy Abuse and Dependence Symptoms:
A Multi-site Study with Three Community Samples
Lawrence M. Scheier1
Arbi Ben Abdallah2, James A. Inciardi 3
Jan Copeland4 and Linda B. Cottler2
1 LARS Research Institute and Washington University School of Medicine, Department of Psychiatry, St. Louis, Missouri, USA
2 Washington University School of Medicine, Department of Psychiatry, St. Louis, Missouri, USA 3 University of Delaware Research Center, Miami, Florida, USA
4 National Drug and Alcohol Research Center, University of New South Wales, Sydney, Australia
National Institute of Drug AbuseDA 14854
![Page 58: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/58.jpg)
Figure 2. Latent class conditional probabilities for THREE cluster model.
![Page 59: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/59.jpg)
Additional Findings
Presented last year comparisons of findings for Ecstasy users who also used hallucinogens– there were specific and unique findings for each drug
Presented comparisons for Ecstasy users who also used stimulants– there were specific and unique findings for each
Ecstasy users can distinguish their symptoms
![Page 60: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/60.jpg)
How do we know it is Ecstasy?
There are many adulterants in the pills. Users tell us they know when they are getting good stuff.
Even use Marquis reagent to test their own pills (DanceSafe)
Hair samples tested
![Page 61: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/61.jpg)
Design of Club Drugs Study in Taipei:
(MRI) Clinical Interview (N=75 +)
(N=75)(N=75)
Random assignment
(1:2)
Time I(N = 150)
Subjects receive:
RBA, SAM and CES-D
Subjects receive: no clinical interview
(all given opportunity to receive clinical SAM)
Subjects receive: Clinical SAM at Tri-Service General Hospital
Time II
Eligibility: 18 to 35 years of age; recruited via flyers, newspaper, respondent driven methods
![Page 62: Epidemiological Evidence for MDMA/Ecstasy Dependence](https://reader035.vdocument.in/reader035/viewer/2022070416/5681513e550346895dbf574b/html5/thumbnails/62.jpg)
Should Ecstasy and its isomers be added separately to the DSM?
Data indicate this to be the case. But, we have just scratched the surface.